10-Q: Theravance Biopharma Reports Q1 2024 Results, Revenue Up 39% Driven by YUPELRI Sales

Theravance Biopharma's first quarter 2024 results show a 39% increase in revenue primarily driven by higher YUPELRI sales, while the company continues to advance its ampreloxetine program.

Summary

• Theravance Biopharma reported a net loss of $11.7 million for the first quarter of 2024, compared to a net loss of $22.1 million in the same period last year.
• Total revenue for the quarter was $14.5 million, a 39% increase year-over-year, primarily due to higher sales of YUPELRI.
• The company's implied 35% share of YUPELRI net sales was $19.3 million, up from $16.4 million in the first quarter of 2023.
• Research and development expenses decreased by 38% to $9.0 million, mainly due to the discontinuation of research activities announced in February 2023.
• Selling, general, and administrative expenses decreased by 13% to $16.7 million.
• The company completed its capital return program in January 2024, repurchasing a total of 31.412 million shares for approximately $325.3 million.
• As of March 31, 2024, Theravance had approximately $100 million in cash, cash equivalents, and marketable securities.
• The company expects its current cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While revenue growth is strong and cost-cutting measures are in place, the company is still operating at a loss and faces significant risks. The completion of the share repurchase program and the progress of the ampreloxetine program are positive signs, but the failure of the Phase 4 study to meet its primary endpoint is a concern. Overall, the sentiment is cautiously optimistic.

Positives

• Revenue increased by 39% year-over-year, indicating strong growth in YUPELRI sales.
• The company's implied share of YUPELRI net sales increased by 18% year-over-year.
• Research and development expenses decreased significantly, reflecting cost-saving measures.
• The company has a strong cash position of approximately $100 million.
• Viatris is progressing with regulatory filings for YUPELRI in China.
• The company completed its share repurchase program.

Negatives

• The company reported a net loss of $11.7 million for the quarter.
• A Phase 4 study comparing YUPELRI to Spiriva HandiHaler did not meet its primary endpoint.
• Interest income decreased due to lower cash balances.

Risks

• The company may not achieve or sustain profitability from operations.
• YUPELRI's acceptance by physicians and patients may not continue to grow.
• Delays in clinical studies or adverse results could harm the business.
• Product candidates may not be approved by regulatory authorities.
• Partners may not fulfill their obligations or may terminate partnerships.
• The company faces substantial competition from companies with more resources.
• The company is subject to extensive regulation and oversight.
• The company may face competition from generic versions of YUPELRI.
• The company depends on single-source manufacturers for its products.
• The company may not receive Milestone Payments or the revenue expected from the Outer Years Royalty related to TRELEGY.
• The company may be subject to product liability claims.
• The company may be subject to data protection laws and regulations.
• The company may be subject to government restrictions on pricing and reimbursement.
• The company may be subject to anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations.
• The company may be subject to environmental, health and safety liabilities.
• The market price for the company's shares may fluctuate widely.
• The company may be treated as a US corporation for US federal income tax purposes.
• The company may be subject to future tax reform.
• The company may be subject to challenges to its structure and transfer pricing arrangements.
• The company may be unable to maintain effective internal controls.
• The company may not be able to protect its intellectual property.
• The company may be subject to litigation to protect or defend its intellectual property.
• The company may be subject to third party claims of intellectual property infringement.
• The company may be subject to activist shareholders.
• The company may be subject to difficulties in protecting their interests because they are incorporated under Cayman Islands law.
• The company may be subject to difficulties in enforcing certain foreign civil liabilities in the Cayman Islands.
• The company may be subject to a lack of securities or industry analyst coverage.
• The company may be subject to a lack of capital appreciation of their ordinary shares.
• The company may be subject to reduced reporting and disclosure requirements as a smaller reporting company.

Future Outlook

The company expects its cash, cash equivalents, and marketable securities will be sufficient to fund its operations for at least the next twelve months based on current operating plans and financial forecasts. Viatris plans to move forward with a registrational filing for YUPELRI in China in mid-2024.

Management Comments

• The company's focus is to deliver medicines that make a difference in people's lives.
• The company is leveraging decades of expertise, which has led to the development of the United States (US) Food and Drug Administration (the FDA) approved YUPELRI (revefenacin) inhalation solution.
• Ampreloxetine has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients.

Industry Context

The report highlights the competitive landscape for COPD treatments, noting that YUPELRI competes with short-acting nebulized bronchodilators. It also mentions the expected launch of Verona Pharma's ensifentrine and Sanofi/Regeneron's Dupixent for COPD, indicating a dynamic market with new entrants. The company is positioning ampreloxetine as a potential first-in-class treatment for MSA patients with symptomatic nOH, where currently only generic droxidopa and midodrine are approved.

Comparison to Industry Standards

• The 39% year-over-year revenue growth is a positive sign, indicating strong market traction for YUPELRI, which is a key driver for the company's revenue.
• The decrease in R&D expenses by 38% is significant and reflects the company's strategic shift away from research activities, which is a common strategy for companies focusing on commercialization.
• The company's cash position of $100 million is relatively strong, providing a financial cushion for ongoing operations and development programs.
• The completion of the $325.3 million share repurchase program is a positive signal to investors, indicating management's confidence in the company's future prospects.
• The company's implied 35% share of YUPELRI net sales of $19.3 million is a key metric to watch, as it directly impacts the company's revenue and profitability.
• The company's ongoing patent litigation with generic companies is a common challenge in the pharmaceutical industry, and the settlements reached with some of these companies are a positive development.
• The company's focus on ampreloxetine for MSA patients with symptomatic nOH is a strategic move into a niche market with limited treatment options, which could provide a competitive advantage.
• The company's reliance on Viatris for the commercialization of YUPELRI is a common practice in the pharmaceutical industry, but it also introduces risks related to the partner's performance and priorities.
• The company's ongoing Phase 3 study for ampreloxetine is a critical milestone, and the results will be closely watched by investors and analysts.
• The company's economic interest in TRELEGY provides a long-term revenue stream, but it is also subject to risks related to GSK's commercialization efforts and market competition.

Legal Proceedings

• The company has settled all litigation with Accord Healthcare, Inc.; Lupin Pharmaceuticals, Inc.; Orbicular Pharmaceutical Technologies Private Limited; and Teva Pharmaceuticals, Inc. regarding generic versions of YUPELRI.
• The patent litigation against the three remaining generic companies, along with certain affiliates, remains pending.

Stakeholder Impact

• Shareholders may benefit from the completed share repurchase program and potential future growth.
• Employees may be affected by the company's cost-cutting measures and strategic shifts.
• Patients may benefit from the development of new treatments for COPD and nOH.
• Customers may benefit from the continued availability of YUPELRI and potential future products.
• Suppliers may be affected by changes in the company's research and development activities.
• Creditors may be affected by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to execute its ampreloxetine registration Phase 3 study (CYPRESS) and prepare for the NDA filing process.
• Viatris plans to move forward with a registrational filing for YUPELRI in China in mid-2024.
• The company will continue to update its long-lived asset impairment assessment each quarterly period.

Key Dates

Keywords

YUPELRI, revefenacin, COPD, Ampreloxetine, TD-9855, neurogenic orthostatic hypotension, MSA, Viatris, TRELEGY, Royalty Pharma, clinical trials, regulatory approval, biopharmaceutical, revenue, research and development, share repurchase